An ophthalmologist and retina specialist, Dr. Roger T. Adler has worked in the field of medicine for more than 20 years. In addition to serving as a doctor at Bond Eye Associates offices in Peoria, Pekin, and Canton, Illinois, Dr. Roger T. Adler is a member of many professional associations including the American Society of Retina Specialists.
The largest organization of its kind, the ASRS is a community of close to 3,000 retina specialists across the United States and around the world. The association is dedicated to expanding research and education opportunities for doctors and advocating for beneficial legislation. One of the society’s many advocacy campaigns included a fight to gain greater access for eye specialists to the drug Avastin, the trade name for the medication bevacizumab.
A 2012 outbreak of fungal meningitis complicated patient access to this drug, which has been found effective for conditions such as age-related macular degeneration. The campaign resulted in the collection of hundreds of letters from ASRS members recommending the Food and Drug Administration (FDA) extend the recently shortened beyond-use dates of “repackaged” bevacizumab; the ASRS argued this restriction by the FDA makes the drug unobtainable for many retina specialists and their patients.
In January, 2017, a revised version of the FDA document pertaining to this matter was released which indicated a step in favor of the ASRS argument – the allowable beyond-use date had been extended.